Drug intelligence / Profile preview

iPSC-derived RPE + PLGA

Development stage: Phase 2
Lead developer: National Eye Institute
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Subretinal

Overview

A cell therapy consisting of autologous induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells grown on a biodegradable poly(lactic-co-glycolic acid) (PLGA) scaffold. This therapy is designed to replace damaged retinal pigment epithelium in patients with retinal degenerative diseases, particularly age-related macular degeneration (AMD) with geographic atrophy. The PLGA scaffold provides structural support for the iPSC-RPE cells while being biodegradable, gradually dissolving in the body after transplantation, leaving no foreign material in the eye.

Other names: iPSC-RPE-PLGA patchauto-iRPE-patchiRPE-patch

Beyond the preview

Go deeper on iPSC-derived RPE + PLGA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iPSC-derived RPE + PLGA.

Explore the full profile